UK | France | Spain | Italy | Germany | USA | Total | ||
---|---|---|---|---|---|---|---|---|
All RVVC sample, during the day of completion of the questionnaire (a) | ||||||||
N | 100 | 107 | 100 | 105 | 106 | 102 | 620 | |
(UK TTO formula) | Mean (Sd) | 0.74 (0.28) | 0.72 (0.25) | 0.67 (0.34) | 0.61 (0.30) | 0.76 (0.25) | 0.68 (0.34) | 0.70 (0.30) |
(country specific formula) | Mean (Sd) | 0.74 (0.28) | 0.77 (0.23) | 0.72 (0.32) | - | 0.86 (0.20) | 0.76 (0.23) | - |
Women with infection, during the day of completion of the questionnaire | ||||||||
N | 5 | 4 | 7 | 7 | 7 | 30 | ||
(UK TTO formula) | Mean (Sd) | - | 0.62 (0.41) | 0.48 (0.30) | 0.73 (0.10) | 0.79 (0.34) | 0.53 (0.33) | 0.64 (0.31) |
(country specific formula) | Mean (Sd) | - | 0.78 (0.22) | 0.73 (0.33) | - | 0.87 (0.20) | 0.77 (0.23) | - |
Women Without infection, during the day of completion of the questionnaire | ||||||||
N | 102 | 96 | 98 | 99 | 95 | 490 | ||
(UK TTO formula) | 0.73 (0.25) | 0.68 (0.34) | 0.60 (0.31) | 0.75 (0.24) | 0.69 (0.34) | 0.69 (0.30) | ||
(country specific formula) | Mean (Sd) | 0.78 (0.22) | 0.73 (0.33) | - | 0.87 (0.20) | 0.77 (0.23) | - | |
General population (b) | ||||||||
N | 3395 | 2892 | 5473 | 4709 | 3552 | 4000 | - | |
Mean (Sd) | 0.92 (0.22) | 0.89 (−) | 0.93 (−) | 0.90 (−) | 0.94 (−) | 0.88 (−) | 0.91 (−) | |
Adjusted mean (Sd) | - | 0.86 (−) | 0.89 (−) | 0.87 (−) | 0.92 (−) | - | - | |
Source | Dennis et al. | König et al. | König et al. | König et al. | König et al. | Kind et al. | - | |
Difference (a - b) | ||||||||
(UK TTO formula) | Mean (Sd) | −0.18 (−) | −0.17 (−) | −0.26 (−) | −0.29 (−) | −0.18 (−) | −0.20 (−) | −0.21 (−) |
Adjusted mean (Sd) | - | −0.14 (−) | −0.22 (−) | −0.26 (−) | −0.16 (−) | - | - | |
(country specific formula) | Mean (Sd) | −0.18 (−) | −0.12 (−) | −0.21 (−) | - | −0.08 (−) | −0.12 (−) | - |
Mean (Sd) (adjusted) | - | −0.09 (−) | −0.17 (−) | - | −0.06 (−) | - | - | |
During the last acute episode (at the completion of the questionnaire or before) (c)* | ||||||||
N | 100 | 107 | 100 | 105 | 106 | 102 | 520 | |
(UK TTO formula) | Mean (Sd) | 0.71 (0.27) | 0.52 (0.33) | 0.48 (0.34) | 0.42 (0.35) | 0.62 (0.28) | 0.51 (0.36) | 0.51 (0.34) |
(country specific formula) | Mean (Sd) | 0.71 (0.27) | 0.59 (0.31) | 0.54 (0.35) | - | 0.76 (0.24) | 0.64 (0.24) | - |
Symptom-free period (at the completion of the questionnaire or before) (d)* | ||||||||
N | 100 | 107 | 100 | 105 | 106 | 102 | 520 | |
(UK TTO formula) | Mean (Sd) | 0.86 (0.24) | 0.72 (0.26) | 0.68 (0.34) | 0.62 (0.31) | 0.77 (0.24) | 0.69 (0.33) | 0.70 (0.30) |
(country specific formula) | Mean (Sd) | 0.86 (0.24) | 0.77 (0.23) | 0.73 (0.32) | - | 0.87 (0.19) | 0.77 (0.23) | - |
Difference (c - d)* | ||||||||
N | 100 | 107 | 100 | 105 | 106 | 102 | 520 | |
Utility score (UK TTO formula) | Mean (Sd) | −0.15 (0.23) | −0.20 (0.29) | −0.20 (0.34) | −0.20 (0.30) | −0.15 (0.23) | −0.18 (0.27) | −0.19 (0.29) |
Utility score (country specific formula) | Mean (Sd) | −0.15 (0.23) | −0.19 (0.25) | −0.19 (0.32) | - | −0.12 (0.20) | −0.12 (0.18) | - |